Making Flexibility Work with Adaptive Clinical Trials

Adaptive clinical trials can allow sponsors to modify aspects of a study as evidence accumulates, potentially reducing development time, cost, and unnecessary patient exposure.

Adaptive designs alongside platform trials, real-world evidence, decentralised trials, Bayesian methods, and seamless Phase I/II approaches are all tools for making clinical development more responsive.

Image

Why Adaptive Clinical Trials Should be Embraced

Traditional clinical trials are largely designed around decisions made before the first participant enters the study.

That traditional structure supports consistency, but it can also make trials slow to respond when accumulating evidence changes the scientific picture.

Adaptive clinical trials introduce pre-planned flexibility.

Depending on the adaptive design, sponsors may be able to modify elements such as sample size, treatment allocation, or continuation decisions without abandoning the underlying statistical framework.

There are several adaptive approaches, including group sequential designs, sample size re-estimation, and multi-arm and multi-stage trials.

The potential advantages of these adaptive approaches include shorter trial times, lower costs, and reduced exposure of participants to ineffective interventions.

The important qualification is that flexibility must be designed in advance. It is not permission to change a study whenever results appear inconvenient.

The U.S. Food and Drug Administration’s (FDA’s) 2019 guidance on adaptive designs for drugs and biologics similarly sets out principles for planning, conducting, and reporting adaptive trials, including Bayesian and more complex designs. 

View interview Is AI Quietly Creating a GDPR Crisis in Clinical Research?

Is AI Quietly Creating a GDPR Crisis in Clinical Research?

Generative AI is transforming clinical trials, but a failure to distinguish between pseudonymised and anonymised data is creating costly regulatory gaps.

Image

Where Adaptive Measures Can Improve Trial Efficiency

Adaptive trial methods become particularly valuable when a study contains decisions that can reasonably be informed by accumulating data.

Group sequential designs

A group sequential approach can include interim analyses that allow a study to stop early when evidence supports efficacy, futility, or another pre-specified decision.

This can prevent participants from continuing in a trial when the central scientific question has already been answered.

Sample size re-estimation

Recruitment assumptions can be wrong. A trial may produce less variability than expected, or the anticipated treatment effect may differ from the original estimate.

Pre-planned sample size re-estimation can allow the study to respond to emerging information, subject to appropriate statistical controls.

Multi-arm, multi-stage designs

Adaptive trial designs allow several interventions to be investigated within one overarching trial structure. Under appropriate rules, unsuccessful treatment arms can be discontinued while promising candidates continue.

This approach can reduce duplication and make better use of trial infrastructure.

Platform trials and Master Protocols, where multiple treatments or disease populations can be evaluated within a shared framework, are also vitally important.

Adaptive Trial Measures Need More Than Statistical Flexibility

The efficiency case is attractive, but adaptive design does not automatically produce a better trial.

There is a very serious need to preserve statistical integrity, while also addressing implementation and regulatory acceptance.

This is where operational design becomes important.

An adaptive protocol may require sophisticated data flows, rapid interim analysis, strong statistical expertise, and clear governance.

Teams must know which decisions can be made, when they can be made, who can make them, and how those decisions will be documented.

The regulatory environment is also evolving.

In September 2025, the FDA published the draft ICH E20 guidance on adaptive trial designs, intended to establish harmonised principles for the planning, conduct, analysis, and interpretation of confirmatory adaptive trials.

The European Medicines Agency has also long addressed adaptive trial designs, highlighting the opportunities for interim modifications while emphasising the prerequisites, methodological problems, and potential pitfalls that need to be considered. 

Therefore, the strategic value of adaptive trials lies in controlled flexibility, not flexibility for its own sake.

Image

Beyond Adaptive Design: A More Responsive Clinical Model

Adaptive trials are part of a much broader transformation in clinical development.

Platform trials and Master Protocols can share infrastructure and control groups and real-world evidence can support external control arms or hybrid designs. Decentralised trials can move selected activities closer to participants. Bayesian approaches can incorporate prior information, while seamless Phase I/II designs can reduce unnecessary separation between early development stages.

These approaches solve different problems, but they point to the same thing.

Clinical development is becoming more data-responsive.

That has implications for sponsors. Trial design should be considered as an integrated scientific system rather than simply a protocol document.

Data quality, technology infrastructure, statistical planning, patient burden, regulatory engagement, and governance all need to work together.

For example, a platform trial may offer substantial efficiency through shared infrastructure, but its analytical complexity can increase. A decentralised trial may improve patient access, but sponsors must manage technology, data integrity, compliance, and safety across a distributed environment.

The opportunity is therefore not to replace conventional randomised controlled trials but to make the underlying architecture more responsive where the scientific question allows it.

Read The Future for Decentralised Clinical Trials

The Future for Decentralised Clinical Trials

Decentralised clinical trials promise to transform drug development and pharma strategy. The evidence tells a complex story. Here is what’s working and what still needs to be fixed.

Image

Clinical Development Needs Flexibility with Discipline

Adaptive clinical trials can make studies more efficient, but only when flexibility is planned, statistically robust, operationally achievable, and acceptable to regulators.

The advantages go well beyond reducing clinical trial timelines and costs. Better-designed adaptive trials can also reduce unnecessary patient exposure and help sponsors make more informed development decisions as evidence accumulates.

At Pharmatica, we examine the systems and strategies reshaping Clinical Development, from adaptive trial design to decentralised research and data-driven decision-making. The future of the Clinical Compass is not less rigour but, rather, smarter flexibility, where trial architecture can respond to evidence without compromising the reliability that patients and regulators depend on.

Pharmatica: Insight. Connection. Impact.